JESDUVROQ (Daprodustat). [package insert] Durham, NC: GlaxoSmithKline. 2023 [cited 08 July 2024]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216951s000lbl.pdf

Yap DYH, McMahon LP, Hao C. Recommendations by the Asian pacific society of nephrology (apsn) on the appropriate use of hif-ph inhibitors. Nephrology. 2020;26:105–18.

Article  PubMed  Google Scholar 

Gupta N, Wish JB. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. Am J Kidney Dis. 2017;69(6):815–26.

Article  CAS  PubMed  Google Scholar 

Akizawa T, Nangaku M, Yonekawa T, Okuda N, Kawamatsu S, Onoue T, et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial. Clin J Am Soc Nephrol. 2020;15(8):1155–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meadowcroft AM, Cizman B, Holdstock L, Biswas N, Johnson BM, Jones D, et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. Clin Kidney J. 2019;12(1):139–48.

Article  CAS  PubMed  Google Scholar 

Mahar KM, Johnson BM. Population Kinetic/Pharmacodynamic (K/PD) Analyses of Daprodustat (Prolyl Hydroxylase Inhibitor) in Non-dialysis (ND) and Hemodialysis-Dependent (HDD) Anemia Patients with Chronic Kidney Disease (CKD). J Pharmacokinet Pharmacodyn. 2018;45(1):T-041.

Google Scholar 

Mactier R, Davies S, Dudley C, Harden P, Jones C, Kanagasundaram S, et al. Summary of the 5th edition of the renal association clinical practice guidelines (2009–2012). Nephron Clin Pract. 2011;118(1):c27–70.

Article  PubMed  Google Scholar 

Mahar K, Mills R, Goyal N. Population Pharmacokinetic (POP-PK) Analysis of Daprodustat (GSK1278863) and its Metabolites in Non-dialysis (ND) and Hemodialysis-Dependent (HDD) Anemia Patients with Chronic Kidney Disease (CKD). J Pharmacokinet Pharmacodyn. 2018;45(S64):T040.

Google Scholar 

Post T, Mahar K, Ashman M. Population pharmacokinetic analysis of daprodustat in healthy volunteers (HV), global phase 2 and Japanese phase 3 studies in chronic kidney disease patients with anemia following once daily (QD) or 3 times weekly (TIW) administration. Clin Pharm Ther. 2021;109:PI-031.

Google Scholar 

Mahar KM, Caltabiano S, Andrews S, Ramanjineyulu B, Chen L, Young G, et al. Clinical pharmacokinetics of daprodustat: results of an absorption, distribution, and excretion study with intravenous microtracer and concomitant oral doses for bioavailability determination. Clin Pharmacol Drug Dev. 2021;10(12):1419–31 (2021-12-01).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Caltabiano S, Cizman B, Burns O, Mahar KM, Johnson BM, Ramanjineyulu B, et al. Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure. Clin Kidney J. 2019;12(5):693–701.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hara K, Takahashi N, Wakamatsu A, Caltabiano S. Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects. Drug Metab Pharmacokinet. 2015;30(6):410–8.

Article  CAS  PubMed  Google Scholar 

Johnson BM, Stier BA, Caltabiano S. Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863. Clin Pharmacol Drug Dev. 2014;3(2):109–17.

Article  CAS  PubMed  Google Scholar 

Mahar KM, Shaddinger BC, Ramanjineyulu B, Andrews S, Caltabiano S, Lindsay AC, Cobitz AR. Pharmacokinetics of daprodustat and metabolites in individuals with normal and impaired hepatic function. Clin Pharmacol Drug Dev. 2022;11(5):562–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Caltabiano S, Mahar KM, Lister K, Tenero D, Ravindranath R, Cizman B, Cobitz AR. The drug interaction potential of daprodustat when coadministered with pioglitazone, rosuvastatin, or trimethoprim in healthy subjects. Pharmacol Res Perspect. 2018;6(2):1–9.

Article  Google Scholar 

Van den Berg P, Post T, Ahsman Mea. Population dose-response analysis of hemoglobin data from global phase 2 and Japanese phase 3 studies with daprodustat in chronic kidney disease patients with anemia following once daily (QD) or 3 times weekly (TIW) administration. Clin Pharmacol Ther. 2021;109.

Food and Drug Administration. Bioanalytic method validation guidance for industry. US Department of Health and Human Services; 2018.

Google Scholar 

Yamada M, Osamura M, Ogura H, Onoue T, Wakamatsu A, Numachi Y, et al. A single-dose, open-label, randomized, two-way crossover study in healthy Japanese participants to evaluate the bioequivalence and the food effect on the pharmacokinetics of daprodustat. Clin Pharmacol Drug Dev. 2020;9(8):978–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahn JE, Karlsson MO, Dunne A, Ludden TM. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn. 2008;35(4):401–21.

Article  PubMed  Google Scholar 

Lehr T, Staab A, Tillmann C, Trommeshauser D, Raschig A, Schaefer HG, Kloft C. Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer’s disease. Br J Clin Pharmacol. 2007;64(1):36–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nguyen TH, Mouksassi MS, Holford N, Al-Huniti N, Freedman I, Hooker AC, et al. Model evaluation of continuous data pharmacometric models: metrics and graphics. CPT Pharmacometrics Syst Pharmacol. 2017;6(2):87–109.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bauer RJ. NONMEM tutorial part ii: estimation methods and advanced examples. CPT Pharmacometrics Syst Pharmacol. 2019;8(8):538–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beal S, Boeckmann L, Bauer R, Sheiner L. NONMEM User’s Guides. (1989–2009). 2009.

Lindbom L, Pihlgren P, Jonsson N. PsN-Toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241–57 (2005/09/01/).

Article  PubMed  Google Scholar 

Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75(2):85–94 (2004/08/01/).

Article  PubMed  Google Scholar 

R Core Team. R: A language and environment for statistical computing. Vienna, Austria. 2020.

Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2008;4(8):1065–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bi YA, Jordan S, King-Ahmad A, West MA, Varma MVS. Mechanistic determinants of daprodustat drug-drug interactions and pharmacokinetics in hepatic dysfunction and chronic kidney disease: significance of OATP1B-CYP2C8 interplay. Clin Pharmacol Ther. 2024;115(6):1336–45.

Article  CAS  PubMed  Google Scholar 

Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm. 1996;24(2):153–72.

Article  CAS  PubMed  Google Scholar 

Gisleskog PO, Karlsson MO, Beal SL. Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn. 2002;29(5–6):473–505.

Article  PubMed  Google Scholar 

Chan Kwong AHP, Calvier EAM, Fabre D, Gattacceca F, Khier S. Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine. J Pharmacokinet Pharmacodyn. 2020;47(5):431–46.

Article  PubMed  PubMed Central  Google Scholar